EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference

BOSTON, Feb. 03, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. EPRS, a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs),  today announced that the Company is scheduled to participate in a fireside chat at the LEERINK Partners

5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:30 a.m. ET.

The link to the live audio webcast and replay of the presentation may be accessed on the EPIRUS' website at http://ir.epirusbiopharma.com/events.cfm.  The webcast will be archived on the Company's website for a period of three months. 

About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals EPRS is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS' goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)ⁱⁱ. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS' website at www.epirusbiopharma.com.